Risk of Newly Diagnosed Type 2 Diabetes Is Reduced in Users of Alendronate

[1]  P. Kostenuik,et al.  Decreased bone remodeling and porosity are associated with improved bone strength in ovariectomized cynomolgus monkeys treated with denosumab, a fully human RANKL antibody. , 2011, Bone.

[2]  Samy Suissa,et al.  Problem of immortal time bias in cohort studies: example using statins for preventing progression of diabetes , 2010, BMJ : British Medical Journal.

[3]  G. Karsenty,et al.  A paradigm of integrative physiology, the crosstalk between bone and energy metabolisms , 2009, Molecular and Cellular Endocrinology.

[4]  G. Karsenty,et al.  Osteocalcin differentially regulates β cell and adipocyte gene expression and affects the development of metabolic diseases in wild-type mice , 2008, Proceedings of the National Academy of Sciences.

[5]  S. Bilgili,et al.  The effect of strontium ranelate on serum insulin like growth factor-1 and leptin levels in osteoporotic post-menopausal women: a prospective study , 2008, Archives of Gynecology and Obstetrics.

[6]  M. McKee,et al.  Endocrine Regulation of Energy Metabolism by the Skeleton , 2007, Cell.

[7]  S. Speciale,et al.  Alendronate reduces the daily consumption of insulin (DCI) in patients with senile type I diabetes and osteoporosis. , 2002, Archives of gerontology and geriatrics.

[8]  T. Lauritzen,et al.  Use and validation of public data files for identification of the diabetic population in a Danish county. , 2001, Danish medical bulletin.

[9]  H. Fleisch.  Bisphosphonates in Bone Disease: From the Laboratory to the Patient , 2000 .

[10]  T. F. Andersen,et al.  The Danish National Hospital Register. A valuable source of data for modern health sciences. , 1999, Danish medical bulletin.

[11]  P. Delmas,et al.  Prevention of early postmenopausal bone loss with cyclical etidronate therapy (a double-blind, placebo-controlled study and 1-year follow-up) , 1997, The Journal of clinical endocrinology and metabolism.

[12]  S. Ortolani,et al.  Effects of oral alendronate and intranasal salmon calcitonin on bone mass and biochemical markers of bone turnover in postmenopausal women with osteoporosis. , 1995, Bone.

[13]  K. Rostgaard,et al.  [The national patient registry. Evaluation of data quality]. , 1995, Ugeskrift for laeger.

[14]  S. Chakrabarti,et al.  Bone mineral metabolism in experimental diabetes mellitus: osteocalcin as a measure of bone remodeling. , 1988, Endocrinology.

[15]  C. Christiansen,et al.  Six and Twelve Month Changes in Bone Turnover are Related to Reduction in Vertebral Fracture Risk During 3 Years of Raloxifene Treatment in Postmenopausal Osteoporosis , 2001, Osteoporosis International.